AtheroNova Receives Russia’s Approval for Phase I Clinical Trials

New Drug Approvals

AtheroNova Receives Russia’s Approval for Phase I Clinical Trials
May 09, 2013
AtheroNova Inc. , a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and to improve lipid profiles in humans, has spent the last few months building up its scientific team ahead of clinical trials. And with Russia’s approval secured, the company is now ready to begin proving AHRO-001.AHRO-001 is a novel drug for the treatment and prevention of atherosclerosis. Rather than just targeting cholesterol levels like Pfizer Inc.’s (NYSE: PFE) Lipitor® statin or Merck & Co.’s (NYSE: MRK) non-statin Zetia®, the company’s drug works by using a pharmacological compound to reduce cholesterol levels as well as potentially regress plaque deposits.AHRO-001 is AtheroNova’s first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AHRO-001 uses certain…

View original post 58 more words

Advertisements

About luciavazine

PHARMA PROFESSIONAL, ITALY
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s